Cargando…

A Comparison of Clinical Prognostic Indices in Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with a Pegylated Liposomal Doxorubicin Combination Regimen in China

BACKGROUND: There is no consensus regarding the risk stratification scores for elderly patients with diffuse large B-cell lymphoma (DLBCL). We aimed to compare the prognostic predictive ability of the current clinical scoring indices in DLBCL elderly patients treated with the R-CODP regimen (rituxim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Hongye, Xu, Yanfeng, Liu, Yanfei, Mi, Lan, Wang, Xiaopei, Liu, Weiping, Zhu, Jun, Song, Yuqin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482890/ https://www.ncbi.nlm.nih.gov/pubmed/36133738 http://dx.doi.org/10.2147/CMAR.S359956

Ejemplares similares

The efficacy and cardiac toxicity of different‐dose pegylated liposomal doxorubicin in elderly patients with diffuse large B lymphoma
por: Li, Li, et al.
Publicado: (2022)

Pegylated liposomal doxorubicin for myeloid neoplasms
por: Zhang, Cheng, et al.
Publicado: (2019)

A tale of the two PEGylated liposomal doxorubicins
por: Chou, Hunghsueh, et al.
Publicado: (2015)

Pegylated liposomal doxorubicin in ovarian cancer
por: Green, Andrew E, et al.
Publicado: (2006)

Pegylated liposomal doxorubicin in ovarian cancer
por: Strother, Robert, et al.
Publicado: (2009)

Pegylated liposomal-encapsulated doxorubicin in cutaneous composite lymphoma: A case report
por: Wollina, Uwe, et al.
Publicado: (2016)

Pulmonary Fibrosis after Pegylated Liposomal Doxorubicin in Elderly Patient with Cutaneous Angiosarcoma
por: Mazzotta, Marco, et al.
Publicado: (2016)

Pegylated liposomal doxorubicin in the management of ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2010)

Conditional survival and hazards of death for peripheral T-cell lymphomas
por: Gao, Hongye, et al.
Publicado: (2021)

Non-Pegylated Liposomal Doxorubicin-Cyclophosphamide in Sequential Regimens with Taxanes as Neoadjuvant Chemotherapy in Breast Cancer Patients
por: Vici, Patrizia, et al.
Publicado: (2014)

Pegylated Liposomal Doxorubicin-induced Palmar-plantar Erythrodysesthesia
por: Moreira-Barros, Joana, et al.
Publicado: (2018)

Prolonged use of pegylated liposomal doxorubicin in gynecologic malignancies
por: Yost, S., et al.
Publicado: (2019)

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
por: Yuan, Zhen, et al.
Publicado: (2021)

Impact of PEGylated Liposomal Doxorubicin and Carboplatin Combination on Glioblastoma
por: Ghaferi, Mohsen, et al.
Publicado: (2022)

Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical Trial
por: Wang, Tiantian, et al.
Publicado: (2022)

Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi’s sarcoma
por: Udhrain, Ashish, et al.
Publicado: (2007)

Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer
por: Pisano, Carmela, et al.
Publicado: (2013)

Pegylated liposomal doxorubicin (PLD)-containing regimen as a novel treatment of monomorphic epithelial intestinal T-cell lymphoma (MEITL): A case report and review of literature
por: Chen, Yue, et al.
Publicado: (2022)

Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma
por: Schmidinger, M, et al.
Publicado: (2001)

Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi’s sarcoma
por: Cainelli, Francesca, et al.
Publicado: (2009)

Pegylated liposomal doxorubicin (PLD): enhanced skin toxicity in areas of vitiligo
por: Yuan, Y, et al.
Publicado: (2008)

Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer
por: Anders, Carey K., et al.
Publicado: (2013)

The role of size in PEGylated liposomal doxorubicin biodistribution and anti‐tumour activity
por: Dadpour, Saba, et al.
Publicado: (2022)

Different situations of identifying second primary malignant tumors in lymphoma patients with synchronous solid tumors
por: Gao, Hongye, et al.
Publicado: (2023)

Serious stomatitis and esophagitis: a peculiar mucous reaction induced by pegylated liposomal doxorubicin
por: Ma, Han, et al.
Publicado: (2015)

Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma
por: Nik, Maryam Ebrahimi, et al.
Publicado: (2019)

Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure
por: Savani, Malvi, et al.
Publicado: (2019)

Cardiac Safety of Pegylated Liposomal Doxorubicin After Conventional Doxorubicin Exposure in Patients With Sarcoma and Breast Cancer
por: Alhaja, Maher, et al.
Publicado: (2023)

Effect of autologous hematopoietic stem cell transplantation for patients with peripheral T-cell lymphoma in China: A propensity score-matched analysis
por: Gao, Hongye, et al.
Publicado: (2022)

Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar
por: Fracasso, P M, et al.
Publicado: (2005)

The Way that PEGyl-DSPC Liposomal Doxorubicin Particles Penetrate into Solid Tumor Tissue
por: Pan, Xing Qing, et al.
Publicado: (2006)

Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)
por: O’Donnell, Robert T., et al.
Publicado: (2009)

A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
por: Huober, Jens, et al.
Publicado: (2010)

Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma
por: Wei, Minyan, et al.
Publicado: (2015)

Pegylated and liposomal doxorubicin is associated with high mortality and causes limited cardiotoxicity in mice
por: Stark, Christoffer, et al.
Publicado: (2018)

Exploring the Use of Pegylated Liposomal Doxorubicin (Caelyx(®)) as Pressurized Intraperitoneal Aerosol Chemotherapy
por: Robella, Manuela, et al.
Publicado: (2019)

Inhibition of Exosome Release Sensitizes U937 Cells to PEGylated Liposomal Doxorubicin
por: Hekmatirad, Shirin, et al.
Publicado: (2021)

Immunotoxicity of multiple dosing regimens of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes.
por: Rahman, A., et al.
Publicado: (1986)

Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma
por: Fu, Zhiying, et al.
Publicado: (2014)

Pegylated Liposomal Doxorubicin in Vindesine-Based and Bortezomib-Based Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study of Efficacy and Safety
por: Zhai, Yujia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9ire14kefgklb3n1vppdjhb0e5